Ronald Aung-Din, MD
Neurology · Sarasota, FLNPI 1215987912
Payments from drug & device makers
Across 1,380 payments — averaging $29.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- SK Life Science, Inc.$3K
- Teva Pharmaceuticals USA, Inc.$3K
- Biogen$2K
- EMD Serono, Inc.$1K
- Eisai Inc.$1K
- plus $26K from 54 others
What the payments were for
- Food & beverage$38,715100%
- Education$450%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$40,770 in reported general payments places this provider in the 80th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 13 | $255,819 |
| VumerityDiroximel Fumarate | 21 | $176,489 |
| RexultiBrexpiprazole | 108 | $163,290 |
| AustedoDeutetrabenazine | 25 | $151,556 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 14 | $151,342 |
| AptiomEslicarbazepine Acetate | 98 | $147,957 |
| Austedo XrDeutetrabenazine | 14 | $97,630 |
| HorizantGabapentin Enacarbil | 58 | $92,365 |
| BriviactBrivaracetam | 40 | $89,414 |
| Wellbutrin XlBupropion Hcl | 13 | $79,363 |
| Nurtec OdtRimegepant Sulfate | 45 | $62,868 |
| UbrelvyUbrogepant | 40 | $60,944 |
| NourianzIstradefylline | 16 | $56,258 |
| AuvelityDextromethorphan Hbr/Bupropion | 41 | $53,407 |
| FycompaPerampanel | 65 | $52,607 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerOctagam, Nurtec Odt | $816 | $318,68758 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $2,507 | $249,18639 claims |
| BiogenVumerity | $1,847 | $176,48921 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,179 | $163,290108 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $324 | $147,95798 claims |
| UCB, Inc.Briviact, Nayzilam | $1,252 | $99,90051 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $246 | $92,36558 claims |
| AbbVieUbrelvy, Qulipta | $4,625 | $80,92357 claims |
| Eisai Inc.Fycompa, Dayvigo | $1,403 | $60,17288 claims |
| Kyowa Kirin, Inc.Nourianz | $400 | $56,25816 claims |
| Axsome Therapeutics, Inc.Auvelity | $903 | $53,40741 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $849 | $46,73672 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,434 neurology providers in Florida.
Other neurology in Sarasota
- Maurico ConchaSarasota$9.1M
- Donald NegroskiSarasota$2.5M
- Mark GoldsteinAtlantis$36.1M
- Derrick RobertsonTampa$27.6M
- Beth SafirsteinHallandale Beach$25.7M
- Michael PfefferMiami$24.5M
- Mark BrodyDelray Beach$20.5M
- Paayal PatelWest Palm Beach$17.3M
- Wendy BondFort Myers$14.7M
- William HoneycuttMaitland$14.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.